Therapeutic gene transfer for rheumatoid arthritis

Abstract Views: 655
PDF: 670
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Rheumatoid arthritis (RA) is a common and severe disease. Its prevalence in adults is about 0.5%. It not only causes joint pain and severe disability but also increases mortality. RA is an inflammatory autoimmune disease whose the inciting stimulus is unknown, but the cascade of immunological and inflammatory reactions has been elucidated. These reactions produce inflammatory synovitis promptly followed by irreversible joint and bone destruction (1). Available treatments for RA fail to provide long-lasting control of the symptoms or disease progression. The beneficial effects of conventional second-line therapy are incomplete and usually short-lived, despite the progress brought by the introduction of methotrexate in the 1980s....

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Boissier, M., & Bessis, N. (2004). Therapeutic gene transfer for rheumatoid arthritis. Reumatismo, 56(s1), 51–61. https://doi.org/10.4081/reumatismo.2004.1s.51